feisty
Louise Newson is a UK-based GP and menopause specialist whose work has done more to shift mainstream thinking on hormone therapy than almost any other clinician in the past decade. Her name comes up constantly in menopause conversations online, in GP offices, and in the offices of specialists who are finally updating their prescribing habits. She founded the Balance menopause platform, wrote the book The Menopause Brain (co-authored with neuroscientist Lisa Mosconi), and built a free app that has been downloaded millions of times. But what does she actually argue, and how much of it stands up?
Who Louise Newson is and why she matters
Newson trained as a GP and began specialising in menopause care when she noticed how poorly the transition was being managed in general practice. Her core position is that menopause is under-diagnosed and undertreated, that HRT (or MHT, as it's now called in Australian clinical settings) has been unfairly demonised since the flawed Women's Health Initiative study in 2002, and that women deserve clear, evidence-based information rather than vague reassurance.
She is not a lone voice. Bodies including the British Menopause Society, the Australasian Menopause Society, and the International Menopause Society have updated their guidelines in ways that broadly align with her central arguments: that body-identical hormones carry a different risk profile than older synthetic ones, that the timing of starting MHT matters, and that quality of life is a legitimate clinical priority.
Her reach is significant. The Balance app had more than 3 million downloads by 2024, and her Balance podcast regularly tops health charts in the UK and Australia. For many women, she is the first clinician they've encountered who actually names their symptoms clearly.
Her main arguments, explained plainly
Newson makes several distinct claims that are worth separating out.
On HRT and breast cancer risk. She argues the breast cancer risk associated with HRT has been overstated and misrepresented. The original WHI study used conjugated equine oestrogen and medroxyprogesterone acetate, not the body-identical oestradiol and micronised progesterone used in most modern prescriptions. She points to evidence suggesting body-identical progesterone does not carry the same risk elevation as synthetic progestogens. Most menopause specialists now agree with this distinction, though the nuance can get lost in public debate.
On perimenopause and diagnosis. Newson has been vocal about how commonly perimenopause is misdiagnosed as depression, anxiety, or simply ageing. She argues that women in their early 40s (and sometimes late 30s) are often dismissed with antidepressants when what they need is a hormone conversation. The complete list of perimenopause symptoms is far longer than most GPs acknowledge, covering brain fog, joint pain, sleep disruption, and palpitations alongside the more familiar hot flushes.
On long-term health benefits of MHT. This is where Newson is most assertive and where some colleagues ask for more caution. She cites evidence linking oestrogen deficiency to increased risk of cardiovascular disease, osteoporosis, and cognitive decline, and argues MHT may protect against all three when started at the right time. The evidence here is real but not settled. The "timing hypothesis" (the idea that starting MHT close to menopause onset gives cardiovascular benefit, while starting late may not) has strong support, but claims about dementia prevention are still emerging from research rather than confirmed by large randomised controlled trials.
Where critics push back
Not everyone agrees with Newson's framing. Some clinicians argue she tips into advocacy in ways that can minimise legitimate uncertainty. A 2023 editorial in The Lancet noted that enthusiasm for MHT, while warranted in many cases, should not translate into universal prescribing without individual risk assessment. Newson herself does not advocate for prescribing without assessment, but the message can get simplified as it spreads online.
There is also a concern that her platform, while enormously useful for raising awareness, functions partly as a commercial ecosystem. The Balance app connects users to private menopause clinics, which critics argue creates an incentive structure that favours prescription. Newson has responded that most NHS services remain inadequately equipped to manage menopause, and private services fill a real gap. That's largely true. But it's worth knowing the context when assessing her recommendations.
What she gets right that too few clinicians say
Set aside the contested edges and Newson's core contribution is hard to overstate. She has given millions of women language for what they are experiencing. She has pushed back on the culture of dismissal that has left women suffering for years before getting a diagnosis or treatment. She has made the case, clearly and repeatedly, that menopause symptoms are not a character test.
Her work also connects to something most clinicians still miss: the physical downstream effects of oestrogen loss. Frozen shoulder, gluteal tendinopathy, and connective tissue changes are real consequences of the hormonal shift, not coincidental complaints in midlife women. Newson names them. Most GPs don't.
Her approach is also practical. The Balance app asks users to track symptoms over time before a consultation, which gives both patient and clinician a clearer picture than a single appointment ever could. That design is genuinely useful, and the fact that it's free matters in a conversation often dominated by expensive private services.
How to use her work
Newson is a resource, not a substitute for your own clinician. Her books and the Balance app are good places to build a vocabulary before a GP appointment. Her podcast episodes with researchers are worth listening to critically rather than as settled fact. And when she cites a study, it's worth checking whether the study design matches the claim being made.
What she offers most reliably is a refusal to accept that menopause should be managed with minimal information and low expectations. On that, the evidence is squarely on her side.